CG Oncology Inc - Bond-003 Cohort P Trial Shows Encouraging Hg-Efs and Well-Tolerated Safety Profile

CG Oncology Inc - Announced Topline Data From Bond-003 Cohort P and First Results From Core-008 Cohort a

CG Oncology Reports Promising Results for Cretostimogene in High-Risk Bladder Cancer Trial

CG Oncology Inc. Files Initial Statement of Beneficial Ownership for Director Christina Rossi

CG Oncology Appoints Christina Rossi to Board as Simone Song Resigns

CG Oncology Announces New Board Member and Board Transition

CG Oncology Unveils Promising Cretostimogene Grenadenorepvec Data in High-Risk Bladder Cancer Trials

CG Oncology Inc. Files Initial Beneficial Ownership Statement for Officer James M. DeTore

CG Oncology Initiated at Buy by Truist Securities

CG Oncology Director Leonard E. Post Reports Sale of Common Shares

Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says

CG Oncology Is Maintained at Outperform by RBC Capital

Morgan Stanley Raises Price Target to CG Oncology to $82 From $79, Keeps Overweight Rating

Calendar of U.S. Earnings Expected in the Week Ahead

U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living

CG Oncology Inc : RBC Raises Target Price to $61 From $53

Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.

CG Oncology Advances Bladder Cancer Therapy Development

BRIEF-Robert Lapetina Resigned As CG Oncology's Interim Financial Officer On Nov 10 - SEC Filing